{"analyses":[{"groupDescription":"two-period crossover design analysis","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"ANOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.6","upperLimit":"11.2","value":"10.5"},{"groupId":"OG001","lowerLimit":"5.5","upperLimit":"7.9","value":"6.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"description":"Cumulative GCSF dose - number of GCSF injections until ANC recovery greater than or equal to 1,000/uL from the start of chemotherapy","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive filgrastim daily SC QD started at 24 hours after completion of chemotherapy and stopped when ANC reaches at least 1,000/uL post nadir.","id":"OG000","title":"Fixed Filgrastim"},{"description":"Patients receive filgrastim SC QD started on the first day after chemotherapy and on any day ANC falls below 1,000/uL and stopped when ANC reaches at least 1,000/uL post nadir.","id":"OG001","title":"Flexible Filgrastim"}],"paramType":"MEAN","populationDescription":"Patients who had data for period 2","reportingStatus":"POSTED","timeFrame":"up until engraftment","title":"Cumulative GCSF Dose","type":"SECONDARY","unitOfMeasure":"Doses"}